quinazolines has been researched along with cyclin d1 in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (39.22) | 29.6817 |
| 2010's | 31 (60.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arteaga, CL; Busse, D; Doughty, RS; Flanagan, WM; Price, JO; Ramsey, TT; Russell, WE; Shawver, LK | 1 |
| Arteaga, CL; Coffey, RJ; Forbes, JT; Lenferink, AE; Shawver, LK; Simpson, JF | 1 |
| Rozengurt, E; Santiskulvong, C; Sinnett-Smith, J | 1 |
| Arteaga, CL; Busse, D; Flanagan, WM; Lenferink, AE; Yakes, FM | 1 |
| Bates, SE; Bishop, PC; Blagosklonny, MV; Fry, DW; Liu, ET; Myers, T; Robey, R | 1 |
| Chan, FL; Chang, C; Huang, J; Lee, YF; Lin, WJ; Messing, EM; Wilding, G | 1 |
| Busse, R; Fisslthaler, B; Fleming, I; Harder, D; Medhora, M; Michaelis, UR | 1 |
| Biddle, A; Davis, TH; Desai, NB; Dmitrovsky, E; Dragnev, KH; Hamilton, M; Iwata, KK; Ma, Y; Memoli, N; Memoli, VA; Nugent, WC; Petty, WJ; Rigas, JR | 1 |
| Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL | 1 |
| Bachelot, F; Beausoleil, E; Bourdin, J; De Oliveira, C; Désiré, L; Drouin, D; Lacombe, S; Leblond, B; Loiseau, N; Peillon, H; Picard, V; Schweighoffer, F; Taverne, T | 1 |
| Adam, L; Bar-Eli, M; Brown, G; Diehl, AJ; Dinney, CP; Kassouf, W; McConkey, DJ | 1 |
| Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S | 1 |
| Bee, T; Black, CC; Dmitrovsky, E; Ewings, KE; Freemantle, SJ; Hattab, EM; Kelley, MR; Krizan, KA; Memoli, VA; Spinella, MJ; Vaseva, AV | 1 |
| Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W | 1 |
| Garber, K | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Bernuau, D; Daniel, F; Güller, M; Legrand, A; Mauviel, A; Michel, L; Toualbi-Abed, K | 1 |
| Brown, PH; Gilmer, TM; Hill, JL; Hilsenbeck, SG; Kim, HT; Li, Y; Osborne, CK; Sexton, KR; Shen, Q; Strecker, TE; Wang, C; Zhang, Y | 1 |
| Andrew, AS; Duell, EJ; Mason, RA; Memoli, V | 1 |
| Bayer-Zubek, V; Cordon-Cardo, C; Costa, J; Donovan, MJ; Greco, FA; Hainsworth, JD; Kotsianti, A; Parums, DV; Teverovskiy, M; Verbel, D | 1 |
| Alvares, EP; Figueiredo, PM; Gama, P; Osaki, LH | 1 |
| Chung, WC; Gold, KA; Hittelman, WN; Kang, SM; Ki Hong, W; Kim, ES; Koo, JS; Lee, J; Ryu, SH | 1 |
| Dragnev, KH; Graham, RM; Memoli, VA; Petty, WJ; Swift, CB; Urbanic, JJ; Varela, VA; Voelzke, WR; Waller, LL | 1 |
| Bhattacharyya, A; Kundu, S; Sengupta, S | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Bhatnagar, PK; Dastidar, SG; Kapoor, S; Nithya, D; Ray, A; Senthil, V; Sharma, A; Talwadkar, A; Tandon, R; Vali, S; Venkataramanan, R | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| Chen, SC; Chiou, SJ; Chuang, LY; Guh, JY; Hwang, CC; Ko, YM; Lin, TD | 1 |
| Benhaim, L; Bohanes, PO; El-Khoueiry, A; El-Khoueiry, R; Gerger, A; Labonte, MJ; Ladner, RD; Lenz, HJ; Ning, Y; Wilson, PM; Yang, D; Zhang, W | 1 |
| Cheng, M; Guo, Q; Li, F; Peng, H; Wang, J; Wang, Y; Zhang, J; Zhao, D; Zhou, Y | 1 |
| Arcaroli, J; Cusatis, G; Garrett-Mayer, E; Hidalgo, M; Messersmith, WA; Rubio-Viqueira, B; Song, D; Weekes, CD; Wilson, LA; Winn, RA | 1 |
| Chlenski, A; Godley, LA; Lu, Z; Raj, JU; Salwen, HR; Tian, Y; Yang, Q | 1 |
| Du, J; Lu, YY; Su, SB; Wang, XF; Zhang, H; Zhang, TL; Zhou, QM | 1 |
| Brautnick, L; Dotson, T; Laudadio, J; Lovato, J; Miller, AA; Petty, WJ; Streer, NP; Weaver, KE | 1 |
| Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ | 1 |
| An, F; Li, M; Lin, P; Liu, J; Liu, L; Wang, P; Zhang, B; Zhao, L; Zhuang, X | 1 |
| Izumi, H; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Watari, K | 1 |
| Kolybo, DV; Komisarenko, SV; Korotkevych, NV; Labyntsev, AJ | 1 |
| Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A | 1 |
| Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A | 1 |
| Feng, S; Hong, D; Wang, Q; Wang, Z; Wei, L; Wen, Z | 1 |
| Dong, F; Liu, X; Luan, C; Luan, S; Shao, H; Sun, C; Zhang, G | 1 |
| Ali, SM; Busaidy, NL; Chmielecki, J; Elvin, JA; Erlich, RL; Heilmann, AM; Khan, SA; Lipson, D; Miller, VA; Murthy, R; Nangia, C; Ross, JS; Shah, MH; Sherman, SI; Stephens, PJ; Subbiah, I; Subbiah, V; Sun, JX; Vergilio, JA; Wang, K; Yelensky, R | 1 |
| Kakudo, K; Nozaki, M; Ohnishi, Y; Yasui, H | 1 |
| Matsuhashi, N; Matsui, S; Okumura, N; Osada, S; Sasaki, Y; Takahashi, T; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yawata, K; Yoshida, K | 1 |
| Emons, G; Girgert, R; Gründker, C | 1 |
| Antonelli, A; Baldini, E; Bocci, G; Di Desidero, T; Elia, G; Fallahi, P; Ferrari, SM; Fioravanti, A; La Motta, C; Materazzi, G; Miccoli, P; Orlandi, P; Paparo, SR; Patrizio, A; Piaggi, S; Ragusa, F; Ruffilli, I; Ulisse, S | 1 |
| Araujo Vieira, I; Brufatto Olguins, D; Brunetto de Farias, C; José Gregianin, L; Kersting, N; Kunzler Souza, B; Lunardi Brunetto, A; Pereira Dos Santos, R; Roesler, R; Schwartsmann, G; Tesainer Brunetto, A | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Zhang, Y | 1 |
| Guo, Z; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Wang, X; Xia, X | 1 |
4 trial(s) available for quinazolines and cyclin d1
| Article | Year |
|---|---|
Bexarotene and erlotinib for aerodigestive tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Phase II trial of dose-dense chemotherapy followed by dose-intense erlotinib for patients with newly diagnosed metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclin D1; Cyclin D3; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Survival; Taxoids; Treatment Outcome | 2013 |
47 other study(ies) available for quinazolines and cyclin d1
| Article | Year |
|---|---|
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity.
Topics: Animals; Cell Cycle Proteins; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Female; G1 Phase; Humans; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Retinoblastoma Protein; Tumor Suppressor Proteins; Tyrphostins; Up-Regulation | 2000 |
Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Topics: Animals; Butadienes; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cysteine Endopeptidases; Dimerization; DNA; Down-Regulation; ErbB Receptors; Female; Humans; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Multienzyme Complexes; Nitriles; Phosphorylation; Proteasome Endopeptidase Complex; Protein Serine-Threonine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Time Factors; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrphostins | 2000 |
EGF receptor function is required in late G(1) for cell cycle progression induced by bombesin and bradykinin.
Topics: 3T3 Cells; Animals; Bombesin; Bradykinin; Cell Cycle; Cell Division; Cell Line; Cyclin D1; Cyclin E; DNA; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; G1 Phase; Kinetics; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Quinazolines; Rats; Receptors, Bombesin; Recombinant Proteins; Transfection; Tyrphostins | 2001 |
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Topics: Breast Neoplasms; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrphostins; Up-Regulation | 2001 |
Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family.
Topics: Cell Cycle; Cell Line, Transformed; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Signaling System; Neoplasm Proteins; Neoplasms; Pyrimidines; Quinazolines; Receptor, ErbB-2; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tyrphostins | 2002 |
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
Topics: Androgen Antagonists; Cell Division; Cyclin D1; Enzyme Activation; ErbB Receptors; Flutamide; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Quinazolines; ras Proteins; Receptors, Androgen; Substance Withdrawal Syndrome; Tyrphostins | 2002 |
Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR).
Topics: 8,11,14-Eicosatrienoic Acid; Allantois; Animals; Aryl Hydrocarbon Hydroxylases; Cell Division; Cell Line; Chick Embryo; Chorion; Cyclin D1; Cytochrome P-450 CYP2C9; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Humans; Neovascularization, Physiologic; Phosphorylation; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Cross-Talk; Tyrphostins | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
Topics: Biomarkers, Tumor; Bronchi; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Cyclin D1; DNA; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Exons; G1 Phase; Gastrointestinal Neoplasms; Gastrointestinal Tract; Humans; Immunoblotting; Immunohistochemistry; Ki-67 Antigen; Kinetics; Luciferases; Necrosis; Neoplasms; Quinazolines; Sequence Analysis, DNA; Time Factors; Transcriptional Activation | 2004 |
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors | 2004 |
RAC1 inhibition targets amyloid precursor protein processing by gamma-secretase and decreases Abeta production in vitro and in vivo.
Topics: Aminoquinolines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Cell Line; Cyclin D1; Dose-Response Relationship, Drug; Endopeptidases; Enzyme Inhibitors; Guinea Pigs; Humans; Male; Molecular Structure; NF-kappa B; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-jun; Pyrimidines; Pyrones; Quinazolines; Quinolines; rac1 GTP-Binding Protein | 2005 |
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Growth Processes; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Urinary Bladder Neoplasms | 2005 |
Repression of cyclin D1 as a target for germ cell tumors.
Topics: Antineoplastic Agents; Cell Differentiation; Cyclin D1; DNA Fragmentation; Enzyme Inhibitors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Germ Cell and Embryonal; Quinazolines; Receptors, Retinoic Acid; RNA, Heterogeneous Nuclear; RNA, Small Interfering; Time Factors; Tretinoin | 2007 |
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin D1.
Topics: Cell Cycle; Cell Nucleus; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Cyclin D1; Cyclin-Dependent Kinase Inhibitor Proteins; Cyclin-Dependent Kinases; Cycloheximide; ErbB Receptors; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatocytes; Humans; Kinetics; Phosphorylation; Protein Kinase Inhibitors; Protein Stability; Protein Synthesis Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Transfection; Tyrphostins; Up-Regulation | 2008 |
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclin D1; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Precancerous Conditions; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; RNA, Messenger; Signal Transduction | 2009 |
Arsenic activates EGFR pathway signaling in the lung.
Topics: Adult; Aged; Amphiregulin; Analysis of Variance; Arsenic; Arsenites; Biomarkers; Bronchi; Cells, Cultured; Cyclin D1; Cycloheximide; EGF Family of Proteins; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung; Lung Neoplasms; Middle Aged; Nails; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Compounds | 2009 |
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cyclin D1; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines; Survival Rate | 2009 |
EGFR is involved in control of gastric cell proliferation through activation of MAPK and Src signalling pathways in early-weaned rats.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Gastric Mucosa; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitosis; Phosphorylation; Quinazolines; Rats; Rats, Wistar; Signal Transduction; src-Family Kinases; Tyrphostins | 2011 |
Prevention of bronchial hyperplasia by EGFR pathway inhibitors in an organotypic culture model.
Topics: Bronchi; Butadienes; Cell Line, Tumor; Cyclin D1; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Hyperplasia; Luciferases; Lung Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Nitriles; Organ Culture Techniques; Quinazolines; RNA, Small Interfering | 2011 |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
Topics: Animals; Biomarkers, Pharmacological; Carcinoma; Cyclin D1; Cyclin D3; Cyclin E; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Quinazolines | 2011 |
EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
Topics: Adenocarcinoma; Antineoplastic Agents; Cadmium Chloride; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Environmental Pollutants; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lethal Dose 50; Lung Neoplasms; Microscopy, Acoustic; Proliferating Cell Nuclear Antigen; Quinazolines; Up-Regulation | 2011 |
Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Computational Biology; Cyclin D1; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1 | 2011 |
Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.
Topics: Animals; Benzamides; Cell Line; Collagen; Cyclin D1; Dioxoles; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; Gefitinib; Imidazoles; Kidney; MAP Kinase Signaling System; Mice; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Quinazolines; Rats; Receptors, Transforming Growth Factor beta; Smad Proteins; Transforming Growth Factor beta1; Translational Research, Biomedical | 2011 |
The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclin D1; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Genetic Association Studies; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Treatment Outcome | 2012 |
LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Humans; Lim Kinases; MAP Kinase Kinase 1; Matrix Metalloproteinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Molecular; Molecular Structure; Neoplasm Invasiveness; p21-Activated Kinases; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pseudopodia; Quinazolines; Signal Transduction; Stomach Neoplasms; Structure-Activity Relationship; Transfection | 2012 |
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Quinazolines; Receptors, CXCR; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2012 |
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Topics: Apoptosis; Azepines; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; DNA Methylation; Doxorubicin; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Quinazolines | 2013 |
Evodiamine induces apoptosis and inhibits metastasis in MDA‑MB-231 human breast cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptors, Urokinase Plasminogen Activator; Resting Phase, Cell Cycle; Urokinase-Type Plasminogen Activator | 2013 |
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones | 2014 |
Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Phosphoproteins; Proto-Oncogene Proteins c-akt; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2014 |
CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclin D1; DNA Methylation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2015 |
The Soluble Heparin-Binding EGF-Like Growth Factor Stimulates EGF Receptor Trafficking to the Nucleus.
Topics: Cell Line; Cell Nucleus; Cyclin D1; ErbB Receptors; Heparin-binding EGF-like Growth Factor; Humans; Ligands; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Tyrphostins | 2015 |
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin | 2015 |
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid | 2015 |
Evodiamine, a novel inhibitor of the Wnt pathway, inhibits the self-renewal of gastric cancer stem cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Epithelial-Mesenchymal Transition; Flow Cytometry; Humans; Kruppel-Like Factor 4; Molecular Structure; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Quinazolines; Snail Family Transcription Factors; Stomach Neoplasms; Transcription Factors; Twist-Related Protein 1; Wnt Signaling Pathway | 2015 |
Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARγ) pathway.
Topics: Anilides; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia; PPAR gamma; Quinazolines | 2016 |
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Topics: Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Drug Resistance, Neoplasm; Everolimus; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methionine; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; Threonine; Thyroid Neoplasms | 2016 |
Lapatinib-resistant cancer cells possessing epithelial cancer stem cell properties develop sensitivity during sphere formation by activation of the ErbB/AKT/cyclin D2 pathway.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Cyclin D2; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Mouth Neoplasms; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2016 |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Female; Fluorouracil; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Stomach Neoplasms; Thymidylate Synthase; Tumor Burden | 2016 |
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Topics: Antineoplastic Agents; Aromatase; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin D1; ErbB Receptors; Estradiol; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Phosphorylation; Quinazolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; src-Family Kinases; Triple Negative Breast Neoplasms | 2017 |
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Epidermal Growth Factor Receptor Regulation of Ewing Sarcoma Cell Function.
Topics: Bone Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Quinazolines; Sarcoma, Ewing; Signal Transduction; Tumor Suppressor Protein p53; Tyrphostins | 2018 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Marsdenia Tenacissima Extract Inhibits Proliferation and Promotes Apoptosis in Human Ovarian Cancer Cells.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; China; Cyclin B1; Cyclin D1; Down-Regulation; Female; Humans; Marsdenia; Ovarian Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Inhibition of EGFR signaling with Spautin-1 represents a novel therapeutics for prostate cancer.
Topics: Animals; Apoptosis; Autophagy; Benzamides; Benzylamines; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Disease Models, Animal; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Glucose; Glucose Transporter Type 1; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Models, Biological; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |